Mithra Enrols its First 5 Patients for the Donesta® Phase II Clinical Study MIT-DO0001-C201


Liège, Belgium 13 May 2016 –  Mithra Pharmaceuticals, a company dedicated to Women’s Health, announces today the enrolment of its first 5 patients in Poland for its Phase II clinical trial MIT-Do0001-C201 (E4Relief) for Donesta®, its Estetrol-based product candidate in the menopause indication. This enrolment is in line with the envisaged timing and objectives, as it was planned for H2 2016, as already announced in Mithra’s IPO Prospectus.

Read the Press Release